An evaluation of no-treatment decisions in patients with newly diagnosed acute myeloid leukemia

Am J Hematol. 2021 Jan;96(1):E17-E20. doi: 10.1002/ajh.26012. Epub 2020 Oct 23.

Affiliations

¹ Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
² Institute of Health Economics, Edmonton, Alberta, Canada.
³ Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

PMID: 33021743
DOI: 10.1002/ajh.26012

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Adolescent
Adult
Aftercare
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Clinical Decision-Making*
Cytarabine / administration & dosage
Databases, Factual*
Disease-Free Survival
Female
Humans
Idarubicin / administration & dosage
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / mortality
Male
Middle Aged
Survival Rate

Substances

Cytarabine
Idarubicin